Article Sidebar
Views PDF: 242
In Silico Screening Of Xanthone Compounds With Α-Glucosidase Inhibitory Activity Targeting Type 2 Diabetes Treatment
Main Article Content
Abstract
Xanthone has various biological effects, including anti-oxidase, anti-microbial, cytotoxic, and anti-cancer. α-glucosidase is an enzyme that plays an important role in converting carbohydrates into glucose, increasing blood sugar in the body to increase the risk of diabetes. In this study, we evaluated the ability of α-glucosidase enzyme inhibition of 133 compounds xanthone by molecular docking method. Finally, we obtained the 4 most potential compounds: mangostanol, isonormangostin, cudraxanthone B, and isojacareubin. Therefore, these compounds have the potential to become drugs for the treatment of type 2 diabetes in the future and need to be studied further.
Article Details
Keywords
Xanthone, α-glucosidase, type 2 diabetes, molecular docking, mangostanol, isonormangostin, cudraxanthone B, isojacareubin.
References
2. Huang, Q., et al., Xanthone glucosides: Isolation, bioactivity and synthesis. Molecules, 2021. 26(18): p. 5575.
3. Ahmadi, S., et al., SMILES-based QSAR and molecular docking study of xanthone derivatives as alpha- glucosidase inhibitors. J Recept Signal Transduct Res, 2022. 42(4): p. 361-372.
4. Gohlke, H., M. Hendlich, and G. Klebe, Knowledge-based scoring function to predict protein-ligand interactions. Journal of molecular biology, 2000. 295(2): p. 337-356.
5. Hanefeld, M. and F. Schaper, Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
EXpert Rev Cardiovasc Ther, 2008. 6(2): p. 153-63.
6. Yuan, X., et al., Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo. Scientific reports, 2015. 5(1): p. 1-13.